Back to discover

Protein / target

Parathyroid hormone/parathyroid hormone-related peptide receptor

Encoded byPTH1RQ03431Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
5
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Structure with Ligand

Protein at a glance

Biological role

G protein-coupled peptide receptor

Strongest disease association

metaphyseal chondrodysplasia, Jansen type

Via encoding gene PTH1R · Genetic evidence · score 0.85

Therapeutic position

Established drug target

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH).

View complete UniProt function annotation

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8397094). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) (PubMed:30975883, PubMed:35932760). PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:20172855, PubMed:30975883, PubMed:35932760). PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH (PubMed:35932760)

Subcellular location

Cell membrane
Domains and Gene Ontology detail (20)

Gene Ontology

  • Capical plasma membrane
  • Cbasolateral plasma membrane
  • Ccytoplasm
  • Cnucleus
  • Cplasma membrane
  • Creceptor complex
  • FG protein-coupled peptide receptor activity
  • FG protein-coupled receptor activity
  • Fparathyroid hormone receptor activity
  • Fpeptide hormone binding
  • Fprotein homodimerization activity
  • Padenylate cyclase-activating G protein-coupled receptor signaling pathway

593 aa · 66 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

G protein-coupled signallingUniProt · GO
View supporting evidence

G protein-coupled signalling

  • ·G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-rel…
  • ·G protein-coupled peptide receptor activity
  • ·G protein-coupled receptor activity
  • ·adenylate cyclase-activating G protein-coupled receptor signaling pathway
View underlying pathways (2)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

PTHLHPTHGNASLRP6ARRB1ARRB2PTH2GNAQGNAI1GNA11PTH1R

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

3 medicines · 3 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Osteoporosis, Postmenopausal3 medicines
Osteoporosis2 medicines
Hypoparathyroidism1 medicine

5 medicines meet Open Targets' target-level approved-medicine definition; the 3 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

3

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

Parathyroid Hormone
Narrow target profileApprovedAgonist

Parathyroid hormone receptor agonist

Indicated for Hypoparathyroidism, Osteoporosis, Postmenopausal

Direct interaction with this protein · Only this protein recorded as a target

abaloparatide
Narrow target profileApprovedAgonist

Parathyroid hormone receptor agonist

Indicated for Osteoporosis, Osteoporosis, Postmenopausal

Direct interaction with this protein · Only this protein recorded as a target

teriparatide
Narrow target profileApprovedAgonist

Parathyroid hormone receptor agonist

Indicated for Osteoporosis, Osteoporosis, Postmenopausal

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene PTH1R

Gene-level evidence surfaced through the gene PTH1Rthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

metaphyseal chondrodysplasia, Jansen type
0.87Well supported

Genetic evidence dominant · Open Targets 0.77

Primary failure of tooth eruption
0.86Well supported

Genetic evidence dominant · Open Targets 0.74

chondrodysplasia Blomstrand type
0.84Well supported

Genetic evidence dominant · Open Targets 0.75

Eiken syndrome
0.82Well supported

Genetic evidence dominant · Open Targets 0.71

Osteoporosis
0.75Well supported

Clinical evidence dominant · Open Targets 0.61

View evidence synthesis (5)
metaphyseal chondrodysplasia, Jansen typeWell supported
0.87
agreement 0.750.99
Genetic87%Animal model12%Literature2%Genetic literaturedup

Open Targets aggregate 0.77 · 3 independent evidence families · 1 not counted as duplicate

Primary failure of tooth eruptionWell supported
0.86
agreement 0.740.98
Genetic81%Animal model10%Literature8%Genetic literaturedup

Open Targets aggregate 0.74 · 3 independent evidence families · 1 not counted as duplicate

chondrodysplasia Blomstrand typeWell supported
0.84
agreement 0.720.96
Genetic86%Animal model13%Literature1%Genetic literaturedup

Open Targets aggregate 0.75 · 3 independent evidence families · 1 not counted as duplicate

Eiken syndromeWell supported
0.82
agreement 0.700.94
Genetic80%Animal model16%Literature4%Genetic literaturedup

Open Targets aggregate 0.71 · 3 independent evidence families · 1 not counted as duplicate

OsteoporosisWell supported
0.75
agreement 0.590.91
Clinical97%Literature3%

Open Targets aggregate 0.61 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
metaphyseal chondrodysplasia, Jansen type0.77
chondrodysplasia Blomstrand type0.75
Primary failure of tooth eruption0.74
Eiken syndrome0.71
Blomstrand lethal chondrodysplasia0.67
Osteoporosis0.61
Hypoparathyroidism0.58
Osteoporosis, Postmenopausal0.56

Drug development

6 compounds recorded · 5 approved · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 3 drugs that target this protein in Forefront's canonical graph (3 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (6)
PARATHYROID HORMONEApproval
PALOPEGTERIPARATIDEApproval
TERIPARATIDE ACETATEApproval
TERIPARATIDEApproval
OSTABOLIN-CPhase 2
ABALOPARATIDEApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and druggable family) — no clinical-stage drug of this modality recorded.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and small molecule binder) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Approved Drug support this modality.

View underlying tractability evidence (9)
SM · Structure with LigandSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMAB · Human Protein Atlas locPR · Database UbiquitinationPR · Small Molecule BinderOC · Approved Drug

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

RECRUITING · via teriparatide · NCT06558188

ACTIVE_NOT_RECRUITING · via abaloparatide · NCT04467983

ENROLLING_BY_INVITATION · via teriparatide · NCT04589819

View all trials (26)

ACTIVE_NOT_RECRUITING · via teriparatide · NCT05151484

NOT_YET_RECRUITING · via abaloparatide · NCT07587775

NOT_YET_RECRUITING · via teriparatide · NCT06303284

COMPLETED · via teriparatide · NCT02176382

COMPLETED · via teriparatide · NCT01705587

COMPLETED · via teriparatide · NCT02090244

COMPLETED · via teriparatide · NCT01400516

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 3 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Label change2026-08-03

    Label change: ABALOPARATIDE (NDA208743)

    fda · regulatory · fda · via abaloparatide

  2. Label change2026-08-03

    Label change: TERIPARATIDE (NDA021318)

    fda · regulatory · fda · via teriparatide

  3. Label change2026-08-03

    Label change: TERIPARATIDE (NDA211939)

    fda · regulatory · fda · via teriparatide

  4. Label change2026-08-03

    Label change: TERIPARATIDE (NDA218771)

    fda · regulatory · fda · via teriparatide

  5. Withdrawn from market2026-07-01

    Market withdrawal: Natpar (EMA)

    ema · market · ema · via Parathyroid Hormone

  6. Regulatory approval2026-04-27

    Approval: Zandoriah (EMA)

    ema · regulatory · ema · via teriparatide

  7. New publication2025-10-01
    Revised European Society of Endocrinology Clinical Practice Guideline: Treatment of Chronic Hypoparathyroidism in Adults.

    European journal of endocrinology · 2025 · 8 citations · Europe PMC · via Parathyroid Hormone

  8. Label change2025-03-28

    Label change: ABALOPARATIDE (NDA208743)

    fda · regulatory · fda · via abaloparatide

  9. Regulatory approval2024-06-04

    Approval: TERIPARATIDE (NDA218771)

    fda · regulatory · fda · via teriparatide

  10. New publication2023-08-01
    Role of Parathyroid Hormone and Parathyroid Hormone-Related Protein in Protein-Energy Malnutrition.

    Frontiers in bioscience (Landmark edition) · 2023 · 5 citations · Europe PMC · via Parathyroid Hormone

  11. New publication2012-10-26
    Combination therapy with risedronate and teriparatide in male osteoporosis.

    Endocrine · 2013 · 58 citations · Europe PMC · via teriparatide

  12. New publication2010-05-24
    Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases.

    Bone · 2010 · 116 citations · Europe PMC · via teriparatide

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.